JP2022513053A5 - - Google Patents

Info

Publication number
JP2022513053A5
JP2022513053A5 JP2021526660A JP2021526660A JP2022513053A5 JP 2022513053 A5 JP2022513053 A5 JP 2022513053A5 JP 2021526660 A JP2021526660 A JP 2021526660A JP 2021526660 A JP2021526660 A JP 2021526660A JP 2022513053 A5 JP2022513053 A5 JP 2022513053A5
Authority
JP
Japan
Prior art keywords
cancer
antibody
cell
amino acid
lymphoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021526660A
Other languages
English (en)
Japanese (ja)
Other versions
JP7682789B2 (ja
JP2022513053A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/061887 external-priority patent/WO2020102779A1/en
Publication of JP2022513053A publication Critical patent/JP2022513053A/ja
Publication of JP2022513053A5 publication Critical patent/JP2022513053A5/ja
Application granted granted Critical
Publication of JP7682789B2 publication Critical patent/JP7682789B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021526660A 2018-11-16 2019-11-15 B7-H3のIgVドメインに対するモノクローナル抗体及びその使用 Active JP7682789B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862768128P 2018-11-16 2018-11-16
US62/768,128 2018-11-16
PCT/US2019/061887 WO2020102779A1 (en) 2018-11-16 2019-11-15 MONOCLONAL ANTIBODIES AGAINST IgV DOMAIN OF B7-H3 AND USES THEREOF

Publications (3)

Publication Number Publication Date
JP2022513053A JP2022513053A (ja) 2022-02-07
JP2022513053A5 true JP2022513053A5 (cg-RX-API-DMAC7.html) 2022-11-08
JP7682789B2 JP7682789B2 (ja) 2025-05-26

Family

ID=70731685

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021526660A Active JP7682789B2 (ja) 2018-11-16 2019-11-15 B7-H3のIgVドメインに対するモノクローナル抗体及びその使用

Country Status (5)

Country Link
US (1) US12252538B2 (cg-RX-API-DMAC7.html)
EP (1) EP3880712A4 (cg-RX-API-DMAC7.html)
JP (1) JP7682789B2 (cg-RX-API-DMAC7.html)
CN (1) CN113330034A (cg-RX-API-DMAC7.html)
WO (1) WO2020102779A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022081888A1 (en) * 2020-10-15 2022-04-21 The Regents Of The University Of California Anti-cancer inhibitory antibodies
CN120093941A (zh) 2021-02-09 2025-06-06 苏州宜联生物医药有限公司 生物活性物偶联物及其制备方法和用途
CN117321087A (zh) 2021-03-26 2023-12-29 先天制药公司 包含与细胞因子融合用于nk细胞衔接的nkp46结合位点、癌抗原结合位点的多特异性蛋白质
WO2022258691A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
WO2022258678A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
CN117616050A (zh) 2021-06-09 2024-02-27 先天制药公司 与nkp46、细胞因子受体、肿瘤抗原和cd16a结合的多特异性蛋白质
CN113527493B (zh) * 2021-07-20 2023-10-27 广州爱思迈生物医药科技有限公司 一种b7-h3抗体及其应用
CN114380910B (zh) * 2022-01-07 2023-04-28 苏州旭光科星抗体生物科技有限公司 靶向人b7-h3分子的人源化单克隆抗体及其应用
EP4480499A1 (en) 2022-02-16 2024-12-25 Medilink Therapeutics (Suzhou) Co., Ltd. Conjugate of antibody-eribulin or derivative thereof, intermediate thereof, preparation method therefor, pharmaceutical composition thereof and use thereof
EP4527415A1 (en) 2022-05-18 2025-03-26 Medilink Therapeutics (Suzhou) Co., Ltd. Antibody-drug conjugate containing protein degradation agent bioactive compound, method for preparing same, and use thereof
CN116063521B (zh) * 2022-10-31 2024-05-14 北京奇迈永华生物科技有限公司 靶向bcma的抗体及其所构成的嵌合抗原受体
US20260201038A1 (en) * 2022-11-15 2026-07-16 CellabMED Inc. Antibody specifically binding to b7-h3
WO2024208818A1 (en) 2023-04-04 2024-10-10 Innate Pharma Modular chimeric antigen receptor
WO2024238966A1 (en) * 2023-05-18 2024-11-21 RNAimmune, Inc. Anti-pd-l1 antibodies and uses thereof
WO2025019228A1 (en) * 2023-07-20 2025-01-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fully human monoclonal antibodies and chimeric antigen receptors against cd276 for the treatment of solid tumors
CN119454937A (zh) 2023-11-13 2025-02-18 苏州宜联生物医药有限公司 抗b7h3抗体-药物偶联物治疗癌症的方法
TW202528354A (zh) * 2024-01-03 2025-07-16 中國商北京泰德製藥股份有限公司 B7-h3結合蛋白及其用途

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
AU2472400A (en) 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US7514537B2 (en) 2001-04-30 2009-04-07 City Of Hope Chimeric immunoreceptor useful in treating human gliomas
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US7390885B2 (en) * 2001-11-26 2008-06-24 Cell Matrix, Inc. Humanized collagen antibodies and related methods
ES2381557T3 (es) 2004-08-03 2012-05-29 Innate Pharma Métodos terapéuticos y de diagnóstico y composiciones para determinar 4IG-B7-H3 y su receptor homólogo en las células NK
WO2006076678A2 (en) 2005-01-13 2006-07-20 The Johns Hopkins University Prostate stem cell antigen vaccines and uses thereof
WO2006117910A1 (ja) * 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. 抗血小板膜糖蛋白質ⅵモノクローナル抗体
CA2735456C (en) 2008-08-26 2021-11-16 City Of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
EP2258719A1 (en) 2009-05-19 2010-12-08 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Multiple target T cell receptor
GB0908816D0 (en) * 2009-05-21 2009-07-01 Royal Holloway University Of L Method
DK2542256T3 (da) 2010-03-04 2019-08-26 Macrogenics Inc Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf
EP2703486B1 (en) 2011-04-25 2018-03-07 Daiichi Sankyo Company, Limited Anti-b7-h3 antibody
LT2884999T (lt) 2012-08-20 2021-04-12 Fred Hutchinson Cancer Research Center Ląstelinės imunoterapijos būdas ir kompozicijos
US9790282B2 (en) 2013-03-25 2017-10-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-CD276 polypeptides, proteins, and chimeric antigen receptors
JP2016531920A (ja) 2013-09-05 2016-10-13 アデュロ・バイオテック・ホールディングス・ヨーロッパ・ベスローテン・フエンノートシャップAduro Biotech Holdings, Europe B.V. Cd70結合ペプチドおよびそれに関連する方法、プロセスおよび用途
CN122399016A (zh) 2014-03-15 2026-07-17 诺华股份有限公司 使用嵌合抗原受体治疗癌症
EP3149040A1 (en) 2014-05-29 2017-04-05 Spring Bioscience Corporation Anti-b7-h3 antibodies and diagnostic uses thereof
EP3347375B1 (en) 2015-09-10 2020-12-23 The United States of America, as represented by The Secretary, Department of Health and Human Services Anti-cd276 chimeric antigen receptors
UA128469C2 (uk) * 2015-10-08 2024-07-24 Макродженікс, Інк. Спосіб лікування в7-н3-експресуючого раку
CN109069633A (zh) * 2016-04-15 2018-12-21 宏观基因有限公司 新颖的b7-h3-结合分子、其抗体药物缀合物及其使用方法
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
RS61828B1 (sr) 2016-06-08 2021-06-30 Abbvie Inc Anti-b7-h3 antitela i antitelske konjugacije lekova
EP3481869A4 (en) 2016-07-11 2020-02-26 Corvus Pharmaceuticals, Inc. ANTI-CD73 ANTIBODIES
KR20230100748A (ko) 2016-07-28 2023-07-05 노파르티스 아게 키메라 항원 수용체 및 pd-1 억제제의 조합 요법
CA3056474A1 (en) 2017-03-31 2018-10-04 Jiangsu Hengrui Medicine Co., Ltd. B7-h3 antibody, antigen-binding fragment thereof and medical use thereof

Similar Documents

Publication Publication Date Title
Safarzadeh Kozani et al. Nanobody-based CAR-T cells for cancer immunotherapy
CN113227146B (zh) 密蛋白18.2结合部分和其用途
JP7682789B2 (ja) B7-H3のIgVドメインに対するモノクローナル抗体及びその使用
JP2022093564A5 (cg-RX-API-DMAC7.html)
JP2017186337A5 (cg-RX-API-DMAC7.html)
US11913025B2 (en) Antigen-specific T cells and uses thereof
JP2020501531A5 (cg-RX-API-DMAC7.html)
JP2018027952A5 (cg-RX-API-DMAC7.html)
JP2022518925A5 (cg-RX-API-DMAC7.html)
JP2020527144A5 (cg-RX-API-DMAC7.html)
JP2016505513A5 (cg-RX-API-DMAC7.html)
JP2013502913A5 (cg-RX-API-DMAC7.html)
RU2014101669A (ru) Агенты, связывающие белки r-спондины (rspo), и способы их применения
JP2019509055A5 (cg-RX-API-DMAC7.html)
ME02369B (me) Antitela za terapiju kancera koji eksprimira klaudin 6
JP2017537620A5 (cg-RX-API-DMAC7.html)
JP2018507188A5 (cg-RX-API-DMAC7.html)
JP2021508255A5 (cg-RX-API-DMAC7.html)
JP2015527070A5 (cg-RX-API-DMAC7.html)
JP2015502138A5 (cg-RX-API-DMAC7.html)
JP2012501626A5 (cg-RX-API-DMAC7.html)
HRP20150256T1 (hr) Djelatna sredstva za vezanje notch1-receptora i postupci njihove uporabe
EP3976660A1 (en) Anti-b7-h3 antibodies
JP2022548764A5 (cg-RX-API-DMAC7.html)
JP2023543493A5 (cg-RX-API-DMAC7.html)